Colistin Versus Colistin Combined With Cefoperazone-sulbactam for Multiresistant Acinetobactor Baumannii Ventilator-associated Pneumonia Treatment
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Clinical response
研究概览
简要总结
This study aims to evaluate clinical outcomes of colistin versus colistin in combination with cefoperazone-sulbactam for patients with MDR-AB VAP treatment.
详细描述
MDR-AB (multidrug-resistant Acinetobacter baumannii) has been an increasingly common cause of ventilator-associated pneumonia (VAP) in intensive care unit (ICU). Colistin remains the last available antibiotic choice. Unfortunately, colistin monotherapy is often inadequate for microbiologic eradication and a risk factor of nephrotoxicity and for heteroresistance.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with a diagnosis of VAP due to A. baumannii
排除标准
- •patients who had polymicrobial VAP
- •Patients with pre-existing severe renal failure and/or abnormal liver function tests
- •Patients allergic to colistin or cefoperazone-sulbactam
结局指标
主要结局
Clinical response
时间窗: within one week
Clinical response was defined as observable improvement in the patient's clinical signs/symptoms, including absence of fever (temp\<38ºC) for three consecutive days or more, and decreasing amount and purulence of tracheal secretions
次要结局
- Radiological response(within one week)
研究者
Renuka Kahuja
Principal Investigator
Shaheed Mohtarma Benazir Bhutto Institue of Trauma